Figure 3 | Scientific Reports

Figure 3

From: Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans

Figure 3

Relative abundance of [Pyr1]apelin-13 C-terminal metabolites identified from human plasma identified by LC-MS/MS. (A) peptide sequences of [Pyr1]apelin-13 metabolites identified in human plasma (the RPRL motif required for receptor binding was indicated by (*); (B) relative peak area of the metabolites (n = 6, data represent mean ± SD).

Back to article page